[{"NetIncomeLoss_1_Q2_USD":-219191000.0,"OperatingLeaseLiability_0_Q2_USD":23160000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"MarketableSecuritiesCurrent_0_Q2_USD":328246000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":89546000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":48967000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":79938000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":80654000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":134303000.0,"RestrictedCashCurrent_0_Q2_USD":1572000.0,"InterestPaidNet_2_Q2_USD":6893000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-1829000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-17013000.0,"Depreciation_2_Q2_USD":724000.0,"InventoryRawMaterialsAndSupplies_0_Q2_USD":3700000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":4865000.0,"AssetsCurrent_0_Q2_USD":655126000.0,"DerivativeGainLossOnDerivativeNet_2_Q2_USD":-38264000.0,"DerivativeGainLossOnDerivativeNet_1_Q2_USD":-21180000.0,"PaymentsToAcquireAvailableForSaleSecurities_2_Q2_USD":171281000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":23974000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":23974000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":7062000.0,"ConvertibleDebtNoncurrent_0_Q2_USD":386471000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":5627000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-35000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":44000.0,"Liabilities_0_Q2_USD":841405000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":19125000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":179955000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":95943000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":28195000.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":7473000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":155000000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-1852000.0,"PrepaidExpenseCurrent_0_Q2_USD":18866000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":22519000.0,"ProceedsFromStockPlans_2_Q2_USD":1698000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":1483000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-61000.0,"AccountsReceivableNetCurrent_0_Q2_USD":719000.0,"UnrecognizedTaxBenefits_0_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":8000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":6158000.0,"RestrictedCash_0_Q2_USD":1572000.0,"InvestmentIncomeNonoperating_2_Q2_USD":237000.0,"InvestmentIncomeNonoperating_1_Q2_USD":104000.0,"OtherAssetsCurrent_0_Q2_USD":31228000.0,"IncreaseDecreaseInInventories_2_Q2_USD":3731000.0,"RestrictedStockValueSharesIssuedNetOfTaxWithholdings_1_Q2_USD":-233000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-404562000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-219400000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-3296000.0,"OtherAssetsNoncurrent_0_Q2_USD":16097000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":270764000.0,"IncreaseDecreaseInOtherCurrentAssets_2_Q2_USD":4311000.0,"CommonStockSharesIssued_0_Q2_shares":80956000.0,"Assets_0_Q2_USD":699912000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-209000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1313184000.0,"CurrentIncomeTaxExpenseBenefit_2_Q2_USD":0.0,"CurrentIncomeTaxExpenseBenefit_1_Q2_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-294709000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":719000.0,"CommonStockSharesOutstanding_0_Q2_shares":80956000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":-1712000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-209000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":1190000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":17722000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-1756000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-174000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":732000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-282002000.0,"LiabilitiesCurrent_0_Q2_USD":157787000.0,"AccountsPayableCurrent_0_Q2_USD":5339000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":272336000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":9650000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":26692000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0771,"AdditionalPaidInCapital_0_Q2_USD":1173512000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":1698000.0,"OperatingLeasePayments_2_Q2_USD":2945000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":6750000.0,"NetIncomeLoss_2_Q2_USD":-402850000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":5562000.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":-2758000.0,"StockholdersEquity_0_Q2_USD":-141493000.0,"ProfitLoss_2_Q2_USD":-402850000.0,"ShareBasedCompensation_2_Q2_USD":34161000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":21939000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"DebtConversionConvertedInstrumentAmount1_2_Q2_USD":126129000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":5035000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":623000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":623000.0,"OperatingIncomeLoss_2_Q2_USD":-318878000.0,"OperatingIncomeLoss_1_Q2_USD":-194287000.0,"AllowanceForDoubtfulAccountsReceivable_0_Q2_USD":0.0,"LitigationSettlementAmountAwardedToOtherParty_2_Q2_USD":0.0,"InventoryNet_0_Q2_USD":3731000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":0.0,"DeferredIncomeTaxExpenseBenefit_1_Q2_USD":0.0,"OperatingLeaseCost_2_Q2_USD":2700000.0,"OperatingLeaseCost_1_Q2_USD":1400000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":699912000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":4035000.0,"OperatingExpenses_2_Q2_USD":319501000.0,"OperatingExpenses_1_Q2_USD":194910000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":5675000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-5.04,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-2.72,"PreferredStockValue_0_Q2_USD":0.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":2874000.0,"Ticker":"APLS","CIK":"1492422","name":"APELLIS PHARMACEUTICALS, INC.","OfficialName":"Apellis Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"5553923312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210809"}]